9 years ago

Precision Ocular Secures £15.5 Million Series A Funding for Retinal Therapies

  • Precision Ocular, a UK-based retinal therapeutics company, has raised £15.5 million in Series A funding

  • Investors include Imperial Innovations, Consort Medical plc, NeoMed, V-Bio Ventures, and Hovione Scientia Ltd

  • The company plans to use the funds to develop treatments for retinal diseases like age-related macular degeneration and diabetic macular oedema, and to create next-generation ocular drug delivery systems for cell and gene therapies.

      • ProblemHealthcare

      "Millions of people suffer from retinal diseases, like age-related macular degeneration and diabetic macular oedema. Current treatments are often ineffective or have serious side effects. "

      Solution

      "Precision Ocular has developed a new way to deliver drugs directly to the back of the eye, where they are needed. This technology allows for more targeted treatment and fewer side effects."

      Covered on